Fraser 1991.

Study characteristics
Methods	Trial design: "Double‐blind, double‐dummy, randomised, parallel study"
Participants	Participants: 49 women with endometriosis stage 1‐3 were randomised and 45 were analysed. Mean age: not stated Inclusion criteria: Laparoscopically diagnosed endometriosis Symptomatic Regular menstrual cycle 24‐36 days Not pregnant Negative pap smear Barrier contraception Exclusion criteria: Concurrent disease which may interfere with drug Surgical therapy within 6 months prior to study entry Steroid therapy within 3 months prior to study entry Setting: Australia/New Zealand Timing: not stated
Interventions	Nafarelin 200 mcg twice a day (400 μg/d) IN + placebo PO for 6 months (n = 33) versus Danazol 200 mg three times a day (600 mg/d) PO + placebo IN for 6 months (n = 16)   Subdivisions were made: Stage 1‐2: Subgroup A (27 patients; 2 dropouts) who received intranasal nafarelin acetate 200 pg twice daily,  or Subgroup B (13 patients; no dropouts) who received oral danazol 200 mg 3 times daily. Stage 3: Subgroup A (6 patients; 1 dropout) who received intranasal nafarelin acetate 200 pg twice daily for 6 months followed by conservative laparotomy, or  Subgroup B (3 patients; no dropouts) who received oral danazol 200 mg three times daily followed by conservative laparotomy.
Outcomes	‐ Dyspareunia, pelvic pain, pelvic tenderness, induration ‐ Change in rAFS score ‐ Adverse effects
Notes	Intention‐to‐treat analysis: not stated Sample size calculation: not stated Funding: Syntex Pharmaceuticals International supplied nafarelin acetate, and a grant to cover the expenses of the trial. Note previous version: Authors contacted with regards to allocation concealment. Author replied that the data were difficult to find but would try.
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	"Computer generated list of random numbers"
Allocation concealment (selection bias)	Unclear risk	No details of method used to conceal allocation were provided.
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Placebo pill + placebo nasal spray so patient and investigators were blinded.
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Placebo pill + placebo nasal spray so assessors were blinded.
Incomplete outcome data (attrition bias) All outcomes	Low risk	3/33 participants "dropped out" of intranasal nafarelin group; no "drop outs" from danazol group (0/16)
Selective reporting (reporting bias)	Low risk	The study protocol was not available but it was clear that the published reports included all expected outcomes, including those that were prespecified.
Other bias	Low risk	No other risk of bias detected